Details of the Drug
General Information of Drug (ID: DM41C8E)
Drug Name |
N,N-dimethyl(pyridin-3-yl)methanamine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Dimethyl-pyridin-3-ylmethyl-amine; 2055-21-2; N,N-Dimethyl-1-(pyridin-3-yl)methanamine; CHEMBL331904; N,N-dimethyl-3-Pyridinemethanamine; 3-Pyridinemethanamine, N,N-dimethyl-; N,N-dimethyl(pyridin-3-yl)methanamine; AC1OK4VN; 3-pyridylmethyl dimethylamine; 3-Pyridinylmethyldimethylamine; SCHEMBL3460939; dimethyl(pyridin-3-ylmethyl)amine; MolPort-000-165-254; ZINC4716433; BDBM50119559; AKOS009071365; N,N-dimethyl-1-pyridin-3-ylmethanamine; DB-066238
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 136.19 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||